Sci-Tech News Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech News Today.

Press releases published on July 1, 2026

Jul. 1, 2026

Kyivstar Subsidiary Uklon Launches Visa Acceptance Platform, Strengthening Digital Payments Infrastructure in Ukraine

Indeterminate GlobeNewswire

Jul. 1, 2026

FreedomPay’s Gateway to Giving™ Turns Small Checkout Donations into Big Community Impact, Starting with the Cincinnati Reds Community Fund

Indeterminate GlobeNewswire

Jul. 1, 2026

ibex Honors the Winners of the 5th Annual CX Leadership Awards at CCW Las Vegas

Indeterminate GlobeNewswire

Jul. 1, 2026

JenaValve Recaps Key Highlights Including Late-Breaking Clinical Data from New York Valves 2026

Indeterminate GlobeNewswire

Jul. 1, 2026

Creative Medical Technology Holdings Issues Mid-Year Update

Indeterminate GlobeNewswire

Jul. 1, 2026

Cuentas Executives Double Down on the Company’s Future with Open-Market Stock Purchases

Indeterminate GlobeNewswire

Jul. 1, 2026

MathCo Expands Databricks Center of Excellence to Help Retail and CPG Enterprises Operationalize Agentic AI

Indeterminate GlobeNewswire

Jul. 1, 2026

Rethink Food and Just Salad Roll Out Rethink Food Bowl for July

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtiene la autorización de comercialización en Francia para su biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba has received marketing authorization in France for its biofungicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba verkrijgt in Frankrijk een vergunning voor het in de handel brengen van zijn biofungicide AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba obtém autorização de colocação no mercado em França para o seu biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Amoéba ottiene l’autorizzazione all'immissione in commercio in Francia per il suo biofungicida AXPERA

Indeterminate GlobeNewswire

Jul. 1, 2026

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Indeterminate GlobeNewswire

Jul. 1, 2026

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris

Indeterminate GlobeNewswire

Jul. 1, 2026

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

Indeterminate GlobeNewswire

Jul. 1, 2026

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Indeterminate GlobeNewswire

Jul. 1, 2026

QTREX Engineers Conductivity Itself to Address Quantum Computing’s Cryogenic Heat-Load Barrier

Indeterminate GlobeNewswire

Jul. 1, 2026

Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares

Indeterminate GlobeNewswire